We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00046761
First Posted: October 4, 2002
Last Update Posted: October 11, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ono Pharmaceutical Co. Ltd ( Ono Pharma USA Inc )
  Purpose
The primary objective of this study is to compare the efficacy of ONO-2506 versus placebo in neurological stroke outcome in patients with acute ischemic stroke.

Condition Intervention Phase
Cerebrovascular Accident Drug: ONO-2506 Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke

Further study details as provided by Ono Pharmaceutical Co. Ltd ( Ono Pharma USA Inc ):

Primary Outcome Measures:
  • Modified Rankin Scale

Estimated Enrollment: 1320
Study Start Date: November 2002
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient must have a clinical diagnosis of acute cortical ischemic stroke.
  • Patient must be randomized into the study within six hours after the initial onset of stroke symptoms.
  • Patient must have a measurable focal neurological deficit for a minimum duration of 60 minutes.
  • Patient must have a CT or MRI examination compatible with the clinical diagnosis of acute ischemic stroke.
  • Patient must have had a pre-stroke mRS scale score of 0 or 1.
  • Other inclusion criteria as specified in the study protocol.

Exclusion Criteria:

  • Patient must not have a body weight of more than 125 kg.
  • Patient must not have a CT and/or MRI with evidence of a non-ischemic mechanism, subarachnoid hemorrhage, or primary intracerebral and/or intraventricular hemorrhage.
  • Patient must not have all three of the following findings:

    1. reduced level of consciousness (has score of greater than or equal to two on NIHSS Question 1a)
    2. forced eye deviation or total gaze paresis (has score of 2 on NIHSS Question 2) and
    3. dense hemiplegia (no movement) of upper and lower extremities (i.e., has score of 4 on NIHSS Question 5 regarding motor arm and has score of 4 on NIHSS Question 6 regarding motor leg).
  • Patient must not have neurological signs and symptoms that are rapidly improving.
  • Patient must not have a severe coexisting or terminal systemic disease.
  • Patient must not be pregnant or lactating.
  • Patient must not have impaired hepatic function; bilirubin greater than 2 mg/dL and or ascites.
  • Patient must not have impaired renal function; serum creatinine greater than 2 mg/dL.
  • Patient must not have congestive heart failure.
  • Patient must not have a baseline ECG showing a PR interval greater than 200 milliseconds, or a corrected QT interval of greater than 480 milliseconds, or a history of ventricular arrhythmias, or a Mobitz Type 1 or greater AV block.
  • Patient must not have other exclusion criteria as specified in the study protocol.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00046761


  Show 148 Study Locations
Sponsors and Collaborators
Ono Pharma USA Inc
Investigators
Study Director: Bryan Due, Ph.D. Ono Pharma USA Inc
  More Information

Responsible Party: Ono Pharma USA Inc
ClinicalTrials.gov Identifier: NCT00046761     History of Changes
Other Study ID Numbers: 2506/INT0104
First Submitted: October 2, 2002
First Posted: October 4, 2002
Last Update Posted: October 11, 2012
Last Verified: October 2012

Keywords provided by Ono Pharmaceutical Co. Ltd ( Ono Pharma USA Inc ):
Acute Ischemic Stroke

Additional relevant MeSH terms:
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases